FDA Issues New Guidance on Digital Health Devices for Anxiety and Depression

The FDA continues to regulate digital therapeutics for mental health conditions such as anxiety and depression through its medical device framework. This approach includes enforcement policies developed during the COVID-19 public health emergency and ongoing updates to software as a medical device guidance. The agency has not cleared any digital therapeutics exclusively for men's mental health indications, though broader adult authorizations exist.

What this means

Regulatory documents describe a focus on safety, effectiveness, and clinical evidence requirements for these products in adult populations. Policy development remains active with input from stakeholders.

FDA's regulatory approach to digital therapeutics for anxiety, depression, and other mental health conditions emphasizes broad adult indications and ongoing policy development, with no approvals specifically for men's mental health.

Key takeaways

• The FDA oversees digital therapeutics for mental health under its medical device regulatory framework, including those targeting depression and substance use disorders [1].
• No digital therapeutics have explicit FDA approval solely for men's mental health conditions to date [2].
• The FDA reaffirmed its commitment to developing appropriate regulatory frameworks for digital mental health products, emphasizing safety, effectiveness, and clinical evidence [3].
• Recent workshops and updated draft guidance address software as a medical device in mental health [3].
• Authorized products carry indications for adults more broadly but may impact men's health outcomes [2].

The FDA's Digital Health Center of Excellence serves as the central point for regulatory policy on these tools. Its resources outline pathways for software-based products that meet device standards.

Policy updates draw from the Digital Health Policy Navigator, which tracks draft guidance and related tools. These materials address clinical evaluation needs for mental health applications.

Device clearance listings confirm current authorizations. They show products cleared for general adult use rather than male-specific conditions.

Limitations

There is a lack of specific FDA-cleared digital therapeutics for men's mental health as a defined category. FDA documentation and device clearances refer to adult populations more generally. Updates are ongoing and subject to public comment and further change.